Astaxanthin improves assisted reproductive outcomes in patients with poor ovarian response by alleviating oxidative stress and regulating granulosa cell mitochondrial function
Dongmei Tian, Haonan Ju, Xinghan Cheng, Xin Liang, Shaomi Zhu
Journal:JOURNAL OF REPRODUCTIVE IMMUNOLOGY
IF:3.5
DOI:10.1016/j.jri.2026.104864
PMID:41723936
Published:2026-02-17
research field:氧化应激生物学营养补充线粒体生理学生殖医学辅助生殖技术
Abstract
Poor ovarian response (POR) is a barrier to assisted reproductive technology (ART) success because oxidative stress damages granulosa cells. Follicular fluid samples were prospectively collected from 156 poor ovarian response (POR) patients. A retrospective 1:1 matched analysis was subsequently performed on 60 selected patients (30 with astaxanthin use and 30 without), with the aim of evaluating astaxanthin’s impact on reproductive outcomes and exploring its regulatory effects on oxidative stress and cell survival pathway. Patients who received 37.5 mg astaxanthin (Haematococcus pluvialis oil) twice daily for 60–90 days before ovarian stimulation were compared with those who did not. Baseline characteristics and stimulation indices were similar. The astaxanthin group achieved a higher cumulative clinical pregnancy rate (72.0 % vs. 41.7 %, P = 0.032), while oocyte yield, fertilization and embryo quality were comparable. In follicular fluid, astaxanthin supplementation reduced superoxide dismutase and malondialdehyde, increased catalase and showed a trend towards higher glutathione. Granulosa cells from supplemented patients displayed lower reactive oxygen species and apoptosis. Pro‑apoptotic proteins (Bax, caspase‑3, caspase‑9 and cytochrome c) were down‑regulated and anti‑apoptotic Bcl‑2 and mitophagy markers (LC3B, PINK1 and Parkin) were up‑regulated. Astaxanthin supplementation was associated with improved cumulative pregnancy rates in POR patients undergoing ART. The benefit may involve reduced oxidative stress, upregulation of mitophagy-related markers, and inhibition of granulosa-cell apoptosis, supporting its potential as an adjunct therapy for poor ovarian responders.
本文使用的Yeasen产品


